Discover key insights from Neurocrine Biosciences' Q2 2025 earnings, featuring record INGREZZA growth, CRENESSITY's rapid adoption, and strategic ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2025, and updated its 2025 financial guidance.

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Wednesday reported second-quarter profit of $107.5 million. The San Diego-based company said it had profit of $1.06 per share.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Following the update ...

Neurocrine Biosciences (NBIX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best strong buy healthcare stocks to buy now. On July 22, Morgan ...

Analysts estimate that United Therapeutics will report an earnings per share (EPS) of $6.87. The announcement from United Therapeutics is eagerly anticipated, with investors seeking news of surpassing ...

In terms of consensus rating, Incyte is in the middle compared to its peers. Incyte has the highest revenue growth among its peers. Incyte also has the highest gross profit. However, Incyte has the ...